title: Immune cells: more than simple carriers for systemic delivery of oncolytic viruses.
abstract: Oncolytic virotherapy on its own has numerous drawbacks, including an inability of the virus to actively target tumor cells and systemic toxicities at the high doses necessary to effectively treat tumors. Addition of immune cell-based carriers of oncolytic viruses holds promise as a technique in which oncolytic virus can be delivered directly to tumors in smaller and less toxic doses. Interestingly, the cell carriers themselves have also demonstrated antitumor effects, which can be augmented further by tailoring the appropriate oncolytic virus to the appropriate cell type. This review discusses the multiple factors that go into devising an effective, cell-based delivery system for oncolytic viruses.
authors.affiliation: Department of Surgery, The Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Samuel
authors.initials: S
authors.lastname: Eisenstein
authors.affiliation: Department of Oncological Sciences and Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Shu-Hsia
authors.initials: SH
authors.lastname: Chen
authors.affiliation: Department of Oncological Sciences and Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Ping-Ying
authors.initials: PY
authors.lastname: Pan
keywords: cancer therapy; cell carrier; immune cells; myeloid-derived suppressor cells; oncolytic virus